WO2016071770A3 - Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same - Google Patents
Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same Download PDFInfo
- Publication number
- WO2016071770A3 WO2016071770A3 PCT/IB2015/002303 IB2015002303W WO2016071770A3 WO 2016071770 A3 WO2016071770 A3 WO 2016071770A3 IB 2015002303 W IB2015002303 W IB 2015002303W WO 2016071770 A3 WO2016071770 A3 WO 2016071770A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- cell lymphoma
- mantle cell
- patients
- identifying
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Abstract
Disclosed herein are methods of predicting a likelihood of responsiveness to treatment with ibrutinib in a patient having mantle cell lymphoma and methods of treating a patient having mantle cell lymphoma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462075544P | 2014-11-05 | 2014-11-05 | |
US62/075,544 | 2014-11-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016071770A2 WO2016071770A2 (en) | 2016-05-12 |
WO2016071770A3 true WO2016071770A3 (en) | 2016-08-11 |
Family
ID=55221449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2015/002303 WO2016071770A2 (en) | 2014-11-05 | 2015-11-05 | Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016071770A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016141044A1 (en) | 2015-03-04 | 2016-09-09 | Arizona Board Of Regents On Behalf Of Arizona State University | Erbb4 inhibitors and methods of use thereof |
EP3615695A1 (en) * | 2017-04-24 | 2020-03-04 | Genentech, Inc. | Erbb2/her2 mutations in the transmebrane or juxtamembrane domain |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013059738A2 (en) * | 2011-10-19 | 2013-04-25 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
WO2016019341A1 (en) * | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor |
WO2016022853A1 (en) * | 2014-08-08 | 2016-02-11 | Pharmacyclics Llc | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
-
2015
- 2015-11-05 WO PCT/IB2015/002303 patent/WO2016071770A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013059738A2 (en) * | 2011-10-19 | 2013-04-25 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
WO2016019341A1 (en) * | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor |
WO2016022853A1 (en) * | 2014-08-08 | 2016-02-11 | Pharmacyclics Llc | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
Non-Patent Citations (4)
Title |
---|
AILEEN NOVERO ET AL: "Ibrutinib for B cell malignancies", EXPERIMENTAL HEMATOLOGY & ONCOLOGY, BIOMED CENTRAL LTD, LONDON, UK, vol. 3, no. 1, 28 January 2014 (2014-01-28), pages 4, XP021176524, ISSN: 2162-3619, DOI: 10.1186/2162-3619-3-4 * |
AMIN AALIPOUR ET AL: "Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas", BRITISH JOURNAL OF HAEMATOLOGY, vol. 163, no. 4, 24 September 2013 (2013-09-24), GB, pages 436 - 443, XP055153751, ISSN: 0007-1048, DOI: 10.1111/bjh.12573 * |
ANDREW M. INTLEKOFER ET AL: "Precision therapy for lymphoma-current state and future directions", NATURE REVIEWS CLINICAL ONCOLOGY, vol. 11, no. 10, 1 January 2014 (2014-01-01), NY, US, pages 585 - 596, XP055263742, ISSN: 1759-4774, DOI: 10.1038/nrclinonc.2014.137 * |
BALASUBRAMANIAN SRIRAM ET AL: "78: Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)", vol. 124, no. 21, 1 December 2014 (2014-12-01), pages Abstr.78, XP008179755, ISSN: 0006-4971, Retrieved from the Internet <URL:http://www.bloodjournal.org/content/124/21/78> * |
Also Published As
Publication number | Publication date |
---|---|
WO2016071770A2 (en) | 2016-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016054520A3 (en) | Engineered cell surface proteins and uses thereof | |
EP3229586A4 (en) | Genetically modified cells, tissues, and organs for treating disease | |
SG10201902594QA (en) | Peptidomimetic macrocycles and uses thereof | |
WO2016085632A3 (en) | Microfluidic measurements of the response of an organism to a drug | |
PL2870913T3 (en) | Device for the extraction, storage and/or treatment of blood or other substances of human or animal origin, and for the use of blood compounds or other biological compounds | |
WO2014138429A3 (en) | Peptidomimetic macrocycles and use thereof in regulating hif1alpha | |
IL282627A (en) | Anaerobic blood storage and pathogen inactivation method | |
HK1208144A1 (en) | Artificial biological heart valve and the production methods thereof | |
HK1215540A1 (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases 1 2 | |
EP3194036A4 (en) | Codification and cueing system for human interactions in tennis and other sport and vocational activities | |
DK3065764T6 (en) | Mini-gastrin analog, particularly for use in CCK-2 receptor positive tumor diagnosis and/or treatment | |
BR112014027905A2 (en) | antibody, cell, nucleic acid, methods of identifying a first antibody, inhibiting cell growth, therapeutic treatment, determining the presence of a protein, diagnosing a tumor, and delivering a cytotoxic agent. | |
PL3692017T3 (en) | Sulfur-containing compounds and polymers and the use thereof in electrochemical cells | |
EP3438227A4 (en) | Light-emitting nanoparticles, cell detection method using same, animal treatment method, medical device, cell visualization method, and method for reducing injury to cell | |
EP3176130A4 (en) | Treatment device, sterilization device, sterilization water, and sterilization method | |
EP3200118A4 (en) | Sample traceability device and method for medical research and/or diagnosis | |
WO2011103276A3 (en) | Abdominal wall treatment devices | |
EP3531830A4 (en) | Methods and compositions for identifying and treating patients with small cell lung cancer | |
EP3306720A4 (en) | Electrode complex, and microbial fuel cell and water treatment device using same | |
EP3349742A4 (en) | Use of niclosamide in the treatment of p53-deficient cells | |
WO2016071770A3 (en) | Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same | |
EP3357996A4 (en) | Biological tissue fabrication information generating device, biological tissue fabrication system, and medical expense calculation system | |
EP3476292A4 (en) | Biological rhythm detection device, detection method, and detection program | |
EP3468447A4 (en) | Method and apparatus for detecting wearable device's contact with living body | |
EP3101117A4 (en) | Biological tissue cutting device and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15828369 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15828369 Country of ref document: EP Kind code of ref document: A2 |